# Strategic Priorities Strategic Priorities RareKids-CAN is anchored in three strategic priorities designed to enable meaningful and lasting impact beyond the five-year funding period. These priorities are: Capacity: Strengthening pediatric rare disease clinical trial capacity and advanced therapy medicinal product (ATMP) readiness Matching: Optimizing participant, site, and trial matching Reform: Driving regulatory reform and system innovation Capacity: Strengthening pediatric rare disease clinical trial capacity and advanced therapy medicinal product (ATMP) readiness Strengthening the capacity of Canadian pediatric research institutions and affiliated hospitals to lead and deliver high-quality, innovative pediatric rare disease clinical trials while building readiness for the safe and effective administration of ATMPs (ex-vivo and in-vivo gene therapies, genome editing, antisense oligonucleotides therapies, and cell therapies) across research and clinical settings. Find out more Matching: Optimizing participant, site, and trial matching Optimizing participant, site, and trial matching to improve the efficiency of pediatric rare disease clinical trial initiation and delivery, while increasing Canada’s attractiveness for investment. This priority aims to create an integrated ecosystem that supports patient identification, recruitment, feasibility assessment, site and investigator identification, and registry use. Find out more Reform: Driving regulatory reform and system innovation Driving regulatory reform and system innovation to enable timely access to pediatric rare disease therapies in Canada. Through active engagement with Health Canada and international partners, this priority aims to reduce regulatory barriers across clinical trial development, conduct, and treatment access Find out more Looking Ahead This strategic plan positions RareKids-CAN to deliver meaningful long-term impact by supporting today’s clinical trials while building a stronger and more connected future for pediatric rare disease research in Canada. By strengthening national coordination, advancing regulatory and system innovation, and centering the needs of children and families, RareKids-CAN is helping ensure that promising therapies are delivered more equitably and efficiently.  Read the Full Strategy